Hectorol 52-week open-label safety study in stage 3-4 CKD with secondary hyperparathyroidism

Phase 3, open-label, single-arm trial of doxercalciferol in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Sanofi. Primary endpoints: Incidence of adverse events and serious adverse events, Changes in physical examination findings, vital signs, or laboratory evaluations and 1 more. Started Nov 2007; status: active, not recruiting.